Agile Therapeutics (AGRX) Received its Third Buy in a Row


After Oppenheimer and RBC Capital gave Agile Therapeutics (NASDAQ: AGRX) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Tim Lugo maintained a Buy rating on Agile Therapeutics today. The company’s shares closed last Monday at $1.74.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 8.6% and a 42.9% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agile Therapeutics with a $4.50 average price target, which is a 172.7% upside from current levels. In a report issued on October 31, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.97 and a one-year low of $0.35. Currently, Agile Therapeutics has an average volume of 4.33M.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More on AGRX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts